LOGIN

Brain metastases are a common and serious complication of metastatic melanoma. Up to 50% of patients develop brain metastases during the course of their illness, and approximately 20% of patients have them at first presentation with metastatic disease. This is a Phase 2 study and will look to evaluate the effectiveness of nivolumab and nivolumab combined with ipilimumab in three patient cohorts: cohorts 1 and 3 are melanoma patients with brain metastases that have had no prior localised treatments and no neurological symptoms related to brain metastases, while cohort 2 are melanoma patients with brain metastases who have had a prior failed local therapy or have current neurological symptoms or have leptomeningeal disease

Study Status: Active, not recruiting
Clinical Trials Registry number: ACTRN12614001315606
ClinicalTrials.gov identifier: NCT02374242

Principal Investigator:
Professor Georgina Long
Melanoma Institute Australia (MIA)

 

• Trial Synopsis
• Trial Publications and Presentations